Second quarter 2026 – Driving cost improvements and deleveraging

Elkem reported Q2 2026 EBITDA of NOK 523 million, down from NOK 645 million a year earlier, mainly due to lower silicon sales prices. The company said its transformation is progressing (cost reductions ahead of target; streamlined organization completed) and has strengthened the balance sheet by raising NOK 1.8 billion in new equity and refinancing its main bank facilities. Overall, results are a modest operational headwind but partially offset by deleveraging and liquidity improvements.

Analysis

The key signal is that the turnaround narrative is now subordinated to commodity pricing. Cost cuts and a cleaner balance sheet can defend the downside, but they do not change the fact that EBITDA remains highly exposed to silicon ASPs; the equity raise mainly converts solvency risk into dilution risk. In practice, that usually supports a short-term relief bid in the stock, but it rarely supports a durable rerating until pricing actually turns.

Second-order winners are downstream users of silicon-intensive materials—industrial formulators, specialty chemicals, and manufacturers with input-cost sensitivity—where margin relief should show up with a 1-2 quarter lag. The losers are other high-cost silicon/ferrosilicon producers, especially those with less flexibility to curtail output; lower prices tend to force industry rationalization before demand recovers. If this is driven by broader China-led demand softness rather than one-off oversupply, the read-through is more negative for European industrial end-demand than the company alone suggests.

Near term, any rally on the refinancing news looks tradeable rather than structural. Over 1-3 months, the main falsifier is a stabilization in silicon prices or a sequential EBITDA inflection; over 6-18 months, the thesis only improves if the company can keep deleveraging without another equity call. Consensus appears too willing to treat financing cleanup as operational recovery, when the more important variable is still the cycle.

Key Decisions for Investors

• Short ELKEF on any 5-10% post-print relief rally over the next 1-4 weeks; use the move to fade a financing-led bounce unless silicon ASPs stabilize. Cover if next-quarter EBITDA shows a clear sequential inflection or pricing data turns up.
• Modest RV pair: long DOW / short ELKEF for 1-3 months to express lower input-cost relief accruing faster to downstream users than to the producer. This is a lower-conviction trade, so size small and exit if industrial demand weakens sharply.
• Do not buy ELKEF as a "turnaround" until the market sees at least one quarter of stable-to-rising silicon prices; the equity raise means upside is capped until the balance sheet de-risks further. If exposure is required, prefer waiting for the post-refi dust to settle rather than chasing the headline.
• Set an alert on silicon pricing and next-quarter EBITDA guidance: a >15% sequential EBITDA improvement or a guidance raise would invalidate the short thesis quickly, while continued price weakness would support further downside.